1. Bryan AJ, Kaur R, Robinson G, Thomas NW, Wilson CG. Histological and physiological studies on the intestine of the rat exposed to solutions of Myrj 52 and PEG 2000. Int. J. Pharmaceut. 1980; 7:145-156.

2. Granger DN, Barrowman JA, Kvietys PR. The small intestine. Clin. Gastroint. Physiol. Philadelphia: Saunders, 1985:141-207.

3. Yoffey JM, Cortice FC. Lymphatics, Lymph and the lymphomyeloid complex. Academic Press, New York and London 1970.

4. Tasker RR. The collection of intestinal lymph from normally active rats. J. Physiol (Lond) 1951; 115:292-295.

5. Borgstrom B, Laurell C-B. Studies on lymph and lymph-protein during absorption of fat and saline in rats. Acta Physiol. Scand. 1953; 29:264-280.

6. Simmonds WJ. The relationship between intestinal motility and the flow and rate of fat output in thoracic duct lymph in unaneasthetised rats. Quart. J. Exp. Physiol. 1954; 42:205-221.

7. Harms V, Wright EM. Some characteristics of Na/K ATPase from rat intestinal basal lateral membrane. J. Memb. Biol. 1980; 53:119-128.

8. Uzel C, Conrad ME. Absorption of heme iron. Semin. Hematol. 1998; 35:27-34.

9. Umbreit JN, Conrad ME, Moore EG, Latour LF. Iron absorption and cellular transport: The mobilferrin/paraferritin paradigm. Semin. Hematol. 1998; 35:13-26.

10. Kellow JE, Borody TJ, Phillips SF, Tucker RL. Human interdigestive motility: variations in pattern from esophagus to colon. Gastroenterol. 1986; 91:386-395.

11. Phillips SF. Transit across the ileocolonic junction. In: Drug Delivery and the Gastrointestinal Tract. Wilson CG, Hardy JG, Davis SS (eds) Chichester: Ellis Horwood, 1989:63-74.

12. Phillips SF. Diarrhea: role of the ileocecal sphincter,. In: New Trends in Pathophysiology and Therapy of the Large Bowel. Barbara L, Migioli M, Phillips SF (eds) Amsterdam: Elsevier Science Publishers BY, 1983.

13. Pahlin P-E. Extrinsic nervous control of the ileo-cecal sphincter in the cat. Acta Physiol. Scand. Suppl. 1975; 426:1-32.

14. Munjeri O, Collett JH, Fell JT, Sharma HL, Smith A-M. In vivo behavior of hydrogel beads based on amidated pectins. Drug Deliv. J. Deliv. Targeting Therap. Agents 1998; 5:239-241.

15. Marvola M, Aito H, Pohto P, Kannikoski A, Nykanen S, Kokkonen P. Gastrointestinal transit and concomitant absorption of verapamil from a single-unit sustained-release tablet. Drug Dev. Ind. Pharm. 1987; 13:1593-1609.

16. Kaus LC, Fell JT, Sharma H, Taylor DC. The intestinal transit of of a single non-disintegrating unit. Int. J. Pharmaceut. 1984; 20:315-323.

17. Kerlin P, Phillips SF. Diffential transit of liquids and solid residue through the human ileum. Am. J. Physiol. 1983; 245:G38-G43.

18. Read NW, Al-Janabi MN, Holgate AM, Barber DC, Edwards CA. Simultaneous measurement of gastric emptying, small bowel residence and colonic filling of a solid meal by the use of the gamma camera. Gut 1986; 27:300-308.

19. Malagelada JR, Robertson JS, Brown ML, Remmington M, Duenes JA, Thomforde GM, et al. Intestinal transit of solid and liquid components of a meal in health. Gastroenterol. 1984; 87:1255-1263.

20. Caride CJ. Scintigraphic determination of small intestinal transit time: comparison with the hydrogen breath technique. Gastroenterol. 1984; 86:714-720.

21. Mundy MJ, Wilson CG, Hardy JG. The effect of eating on transit through the small intestine. Nucl. Med. Commun. 1989; 10:45-50.

22. Ollerenshaw KJ, Norman S, Wilson CG, Hardy JG. Exercise and small intestinal transit. Nucl. Med. Commun. 1987; 8:105-110.

23. Oettle GJ. Effect of moderate exercise on bowel habit. Gut 1991; 32:941-944.

24. McMahon FG, Ryan JR, Akdamar K, Ertan A. Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial. Lancet 1982; 2:1059.

25. Shaffer JL, Higham C, Turnberg LA. Hazards of slow-release preparations in patients with bowel strictures. Lancet 1980; 2:487.

26. Whittington RM, Thompson IM. Possible hazard of plastic matrix from slow release tablets [letter]. Lancet 1983; 1:184.

27. Hunter E, Fell JY, Sharma H. The gastric emptying ot pellets contained in hard gelatin capsules. Drug Dev. Ind. Pharm. 1982; 8:751-757.

28. Feinblatt TM, Ferguson Jr EA. Timed disintegration capsules: an in vivo roentgenographic study. N. Engl. J. Med. 1956; 254:940-945.

29. Green MA. One year's experience with sustained release antihistamine medication: experimental and clinical study. Ann. Allergy 1954; 12:273-276.

30. Conrad JM, Robinson JR. Sustained drug release from tablets and particles through coating. In: Pharm. Dosage Forms Tablets. Lieberman, H A, Lachman, L (eds) Marcel Dekker New York:, 1982:149-163.

31. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27:886-892.

32. Davis SS, Khosla R, Wilson CG, Washington N. The gastrointestinal transit of a controlled release pellet formulation of tiaprofenic acid. Int. J. Pharmaceut. 1987; 34:253-258.

33. Fischer W, Boertz A, Davis SS, Khosla R, Cawello W, Sandrock K, Cordes G. Investigation of the gastrointestinal transit and in vivo drug release of isosorbide-5-dinitrate pellets. Pharmaceut. Res. 1987; 4:480-485.

34. Read NW, Miles CA, Fisher D, Holgate AM, Kime ND, Mitchell MA. Transit of a meal through the stomach, small intestine and colon in normal subjects and its role in the pathogenesis of diarrhoea. Gastroenterol. 1980; 79:1276-1282.

35. Groning R, Huen G. Oral dosage forms with controlled gastrointestinal transit. Drug Dev. Ind. Pharm. 1984; 10:527-539.

36. Blackburn NA, Holgate AM, Read NW. Does guar gum improve post-prandial hyperglycaemia in humans by reducing small intestinal contact area? Br. J. Nutr. 1984; 52:197-204.

37. Levy G, Rao BK. Enhanced intestinal absorption of riboflavin from sodium alginate solution in man. J. Pharmaceut. Sci. 1972; 61:279-280.

38. Beerman B, Grochinsky-Grind M. Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food. Europ. J. Clin. Pharm. 1978; 13:125-128.

39. Jeppsson J, .Sjögren J. The influence of food on side effects and absorption of lithium. Acta Psychiatr. Scand. 1975; 51:285-288.

40. Wilson CG, Washington N. Assessment of disintegration and dissolution of dosage forms in vivo using gamma scintigraphy. Drug Dev. Ind. Pharm. 1988; 14:211-218.

41. Bechgaard H, Ladefoged K. Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. J. Pharm. Pharmacol. 1978; 30:690-692.

42. Bogentoft C, Appelgren C, Jonsson U, Sjorgren J, Alpsten M. Intestinal transit time of 51Cr-labelled pellets of different densities. In: Radionuclide Imaging in Drug Research. Wilson CG, Hardy JG, Frier M, Davis SS (eds). London: Croom Helm, 1982:p294.

43. Bechgaard H, Christensen FN, Davis SS, Hardy JG, Taylor M, Whalley DR, Wilson CG. Gastrointestinal transit of pellet systems in ileostomy subjects and the effect of density. J. Pharm. Pharmacol. 1985; 37:718-21.

44. Clarke GM, Newton JM, Short MB. Comparative gastrointestinal transit of pellet systems of varying density. Int. J. Pharmaceut. 1995; 114:1-11.

45. Meyer JH, Elashoff J, Porter-Fink V, Dressman J, Amidon GL. Human postprandial gastric emptying of 1-3 mm spheres. Gastroenterol. 1988; 94:1315-25.

46. Schedl HP, Clifton JA. Cortisol absorption in man. Gastroenterol. 1963; 44:134-145.

47. Beerman B, Hellstrom K, Rosen A. The absorption of orally administered 12 alpha H-digoxin in man. Clin. Sci. 1972; 43:507-510.

48. Delie F, Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit. Rev. Therap. Drug Carrier Syst. 1997; 14:221-286.

49. Hidalgo IJ, Li J. Carrier-mediated transport and efflux mechanisms of Caco-2 cells. Adv. Drug Deliv. Rev. 1996; 22:53-66.

50. Meunier V, Bourrie M, Berger Y, Fabre G. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol. Toxicol. 1995; 11:187-194.

51. Pusztai A. Transport of proteins through the membranes of the adult gastro-intestinal tract—A potential for drug delivery? Adv. Drug Deliv. Rev. 1989; 3:215-228.

52. Yang CY, Dantzig AH, Pidgeon C. Intestinal peptide transport systems and oral drug availability. Pharmaceut. Res. 1999; 16:1331-1343.

53. Nussberger S, Steel A, Hediger M. Structure and pharmacology of proton-linked peptide transporters. J. Cont. Rel. 1997; 46:31-38.

54. Smith PL, Eddy EP, Lee C-P, Wilson G. Exploitation of the intestinal oligopeptide transporter to enhance drug absorption. Drug Deliv J. Deliv. Target. Therap. Agents 1996; 3:117-123.

55. Naisbett B, Woodley J. The potential use of tomato lectin for oral drug delivery: 2. Mechanism of uptake in vitro. Int. J. Pharmaceut. 1994; 110:127-136.

56. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Cont. Rel. 1990; 11:205-214.

57. Hastewell J, Williamson I, Mackay M, Rubas W, Grass GM. Gastrointestinal lymphatic absorption of peptides and proteins. Adv. Drug Deliv. Rev. 1991; 7:15-69.

58. Bernkopf-Schnurch A, Gabor F, Szostak MP, Lubitz W. Gentechnologische herstellung adhasiver arzeistofftrager (Production of adhesive drug carriers using recombinant DNA-technology). Scientia Pharmaceutica 1995; 63:159-166.

59. Hardy JG, Evans DF, Zaki I, Clark AG, Tonnesen HH, Gamst ON. Evaluation of an entericcoated naproxen tablet using gamma scintigraphy and pH monitoring. Int. J. Pharmaceut. 1987; 37:245-250.

60. Lucas M. The surface pH of the intestinal mucosa and its significance in the permeability of organic anions. In: Csaky T.Z. ed, Pharmacology of Intestinal Permeation II, Springer-Verlag, Berlin. 1984:119-163.

61. Kitizawa S, Ito H, Sezak H. Transmucosal fluid movementand its effect on drug absorption. Chem. Pharm. Bull. 1975; 23:1856-1865.

62. Ochensfahrt H, Winne D. The contribution of solvent drag to the intestinal absorption of the acidic drugs benzoic acid and salicyclic acid from the jejunum of the rat. Naunyn. Schmiedebergs Arch. Pharmacol. 1974; 281:175-196.

63. Ochensfahrt H, Winne D. The contribution of solvent drag to the intestinal absorption of the basic drugs amidopyrine and antipyrine from the jejunum of the rat. Naunyn. Schmiedebergs Arch. Pharmacol. 1974; 281:197-217.

64. Gramatte T, Richter K. Paracetamol absorption from different sites in the human small intestine. Br. J. Clin. Pharmacol. 1994; 37:608-611.

65. Gramatte T, El Desoky E, Klotz U. Site-dependent small intestinal absorption of ranitidine. Eur. J. Clini. Pharmacol. 1994; 46:253-259.

66. Watkins P. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 1997; 27:161-170.

67. Thiebaut F, Tsuruo T, Hamada H, Gottesman M, Pastan I, Willingham MC. Cellular localisation of the multi-drug resistant gene product in normal human tissues. Proc. Natl. Acad. Sci. USA 1987; 84:7735-7738.

68. Schinkel AH. P-glycoprotein, a gate-keeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 1999; 36:179-194.

69. Gramatte T, Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal Rverapamil. Clin. Pharmacol. Therap. 1999; 66:239-245.

70. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharmaceut. Sci. 1998; 87:1322-1330.

71. Hebert M. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv. Drug Deliv. Rev. 1997; 27:201214.

Watkins P. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 1987; 27:161-170.

Borgstrom B, Dahlovist A, Lunh G, Sjovall J. Studies of the intestinal digestion and absorption in the human. J. Clin. Invest. 1957; 36:36.

Ho NFH, Merkle HP, Higuchi WI. Quantitative, mechanistic and physiologically realistic approach to the biopharmaceutical design of oral drug delivery systems. Drug Dev. Ind. Pharm. 1983; 9:1111-1184.

Taylor DC, Lynch J, Leahy DE. Models for intestinal permaeability to drugs. In: Drug Delivery to the Gastrointestinal Tract. Hardy JG, Davis SS, Wilson CG, eds. Chichester: Ellis Horwood, 1989:133-145.

Dressman J. Kinetics of drug absorption from the gut. Drug Delivery to the Gastrointestinal Tract. Hardy JG, Davis SS, Wilson CG, eds. Chichester: Ellis Horwood, 1989:195-219.

Toothaker RD, Welling PG. The effect of food on drug bioavailability. Ann Rev. Pharmacol. Toxicol. 1980; 20:173-199.

Pao L-H, Zhou SY, Cook C, Kararli T, Kirchhoff C, Truelove J, et al. Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: Relationship with region-dependent intestinal absorption. Pharmaceut. Res. 1998; 15:221-227.

Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. Therap. 1999; 66:118127.

Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 1997; 99:2545-2553. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharmaceut. Res. 1999; 16:478-485.

Wilkinson GR. The effects of diet, aging and disease states on presystemic elimination and oral drug bioavailability in humans. Adv. Drug Deliv. Rev. 1997; 27:129-159. Briggs MH. Megadose vitamin C and metabolic effects of the pill. Br. Med. J. 1981; 283:1547.

Darbar D, Dell'Orto S, Morike K, Wilkinson GR, Roden D. Dietary salt increases the first pass elimination of oral quinidine. Clin. Pharmacol. Therap. 1997; 61:292-300. Bostrom H, Bromster D, Nordenstram H, Wengle B. On the occurrence of phenol and steroid sulphokinases in the human gastrointestinal tract. Scand. J. Gastroenlerol. 1968; 3:369-374.

Melander A, McLean A. Influence of food intake on the presystemic clearance of drugs. Clin.Pharmacokinet. 1983; 8:286-295.

Melander A. Influence of food on the bioavailability of drugs. Clin. Pharmacokinet. 1978; 3:337-341.

Read NW, Sugden K. Gastrointestinal dynamics and pharmacology for the optimum design of controlled-release oral dosage forms. CRC Crit. Rev. Ther. Drug Carr. 1987; 4:221-267.

Zimmer A, Roth W, Hugemann B, Spieth W, Koss, FW. A novel method to study drug absorption. Evaluation of the sites of absorption with a capsule for wireless controlled drug liberation in the GI tract. Aiche JM, Hirtz J, (eds). First Europ. Congress Biopharmaceut. Pharmacokinet.; 1981.p211.

Graul EH, Loew D, Schuster O. Voraussetzung fur die Entwicklung einer sinnvollen Retard- und Diuretika-Komination. Therapiewoche 1985; 35:4277-4291. Staib AH, Loew D, Harder S, Graul EH, Pfab R. Measurement of theophylline absorptionfrom different regions of the gastro-intestinal tract using a remote controlled drug delivery device . Eur. J. Clin. Pharmacol. 1986; 30:691-697. Bieck PR. Drug absorption from the human colon. In: Drug Delivery to the Gastrointestinal Tract. Wilson CG, Hardy JG, Davis SS. (eds) Chichester: Ellis Horwood, 1989:147-160.

93. Bogentoft C, Alpsten M, Ekenved G. Absorption of acetylsalicylic acid from enteric-coated tablets in relation to gastric emptying and in vivo disintegration. J. Pharm. Pharmacol. 1984; 36:350-351.

94. Noguchi T, Charman WNA, Stella VJ. The effect of lipophilicity and lipid vehicles on the lymphatic transport of various testosterone esters. Int. J. Pharmaceut. 1985; 24:173-184.

95. Vost A, Maclean N. Hydrocarbon transport in chylomicrons and high density lipoproteins in the rat. Lipids 1984; 19:423-435.

96. Charman WNA, Stella VJ. Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. Int. J. Pharmaceut. 1986; 33:165-172.

97. DeMarco TJ, Levine RR. Role of lymphatics in the intestinal absorption and distribution of drugs. J. Pharmacol. Exp. Therap. 1969; 169:142-151.

98. Gianninna T, Steinetz BG, Meli A. Pathway of absorption of orally administered ethynyl estradiol3-cyclopentyl ether in the rat as influenced by vehicle of administration. Proc. Soc. Exp. Biol Med. 1966; 121:1175-1179.

99. Palin KJ, Wilson CG, Davis SS, Phillips AJ. The effects of oils on the lymphatic absorption of DDT. J. Pharm. Pharmacol. 1982; 34:707-710.

100. Palin KJ, Wilson CG. The effect of different oils on the absorption of probucol in the rat. J. Pharm. Pharmacol. 1984; 36:641-643.

101. Bates TR, Sequeira JA. Bioavailability of micronised griseofulvin from corn oil-in-water emulsion, aqueous suspension and commercial tablet dosage forms in humans. J. Pharmaceut. Sci. 1975; 64:793-797.

102. Bjarnason I, Peters TJ. Influence of anti-rheumatic drugs on gut permeability and on the gut associated lymphoid tissue. Baillieres Clin. Rheumatol. 1996; 10:165-176.

103. Choi VMF, Coates JE, Chooi J, Thomson ABR, Russell AS. Small bowel permeability— a variable effect of NSAIDS. Clin. Invest. Med.—Med. Clin. Exp. 1995; 18:357-361.

104. Leijonmarck CE, Raf L. Ulceration of the small intestine due to slow-release potassium chloride tablets. Acta Chir. Scand. 1985; 151:273-278.

105. Skoutakis VA, Acchiardo SR, Wojciechowski NJ. The comparative bioavailability of liquid, wax-matrix and microencapsulated preparations of potassium chloride. J. Clin. Pharmacol. 1985; 25:619-621.

Was this article helpful?

0 0
The Natural Acne Remedy

The Natural Acne Remedy

Download this Guide and Discover 50 Ways To Treat Acne Using Only Natural Remedies. About Time You Got Rid of Your Acne? Inside this guide, you'll discover: 50 ways to treat acne using natural remedies. The benefits of treating acne using natural remedies. Natural acne remedies to treat acne scarring. The side effects of popular acne medicines and treatments plus much, much more.

Get My Free Ebook

Post a comment